Last reviewed · How we verify
half cyclophosphamide
Half-dose cyclophosphamide is a reduced-intensity alkylating agent that cross-links DNA to kill rapidly dividing cells, particularly in cancer and autoimmune contexts.
Half-dose cyclophosphamide is a reduced-intensity alkylating agent that cross-links DNA to kill rapidly dividing cells, particularly in cancer and autoimmune contexts. Used for Cancer conditioning in hematopoietic stem cell transplantation, Autoimmune diseases (as part of reduced-intensity conditioning regimens).
At a glance
| Generic name | half cyclophosphamide |
|---|---|
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris |
| Drug class | Alkylating agent |
| Target | DNA (non-specific alkylation) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cyclophosphamide is a nitrogen mustard alkylating agent that forms DNA cross-links, leading to cell death. The half-dose formulation reduces systemic toxicity while maintaining therapeutic efficacy, often used in combination regimens or for patients with reduced tolerance. This approach is particularly relevant in hematopoietic stem cell transplantation conditioning and certain autoimmune disease protocols.
Approved indications
- Cancer conditioning in hematopoietic stem cell transplantation
- Autoimmune diseases (as part of reduced-intensity conditioning regimens)
Common side effects
- Myelosuppression
- Hemorrhagic cystitis
- Nausea and vomiting
- Alopecia
- Infection
Key clinical trials
- BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) (PHASE2)
- Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts (NA)
- Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL (PHASE1, PHASE2)
- Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL) (EARLY_PHASE1)
- Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies
- Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor (NA)
- Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T (EARLY_PHASE1)
- TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- half cyclophosphamide CI brief — competitive landscape report
- half cyclophosphamide updates RSS · CI watch RSS
- Gustave Roussy, Cancer Campus, Grand Paris portfolio CI